Jove
Visualize
Contact Us

Related Concept Videos

Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

531
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
531
Hemodialysis III: Nursing Management01:25

Hemodialysis III: Nursing Management

1.2K
The nursing management of a patient undergoing hemodialysis includes several critical steps, starting with a thorough assessment before the procedure.Before the Hemodialysis ProcedureFirst, record the patient's vital signs—blood pressure, heart rate, respiratory rate, and temperature—to establish a baseline. This baseline is essential for detecting conditions such as hypotension that could impact the patient's response to dialysis. Document the patient's pre-dialysis weight, as this...
1.2K
Hemodialysis I: Introduction01:25

Hemodialysis I: Introduction

2.2K
Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
2.2K
Hemodialysis II: Procedure and Complications01:24

Hemodialysis II: Procedure and Complications

1.2K
DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
1.2K
Drug Dosing in Renal Diseases: Measurement of Serum Creatinine Concentration and Clearance01:25

Drug Dosing in Renal Diseases: Measurement of Serum Creatinine Concentration and Clearance

294
In healthy individuals, serum creatinine levels remain stable due to a balance between its constant production—primarily from muscle metabolism—and renal excretion. Creatinine is freely filtered by the glomeruli, making it a valuable marker for estimating renal function. When the glomerular filtration rate (GFR) decreases, the kidneys can only eliminate less creatinine, causing serum levels to rise.Serum creatinine concentration is widely used to estimate creatinine clearance...
294
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

455
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
455

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of calcimimetic use with lower mortality in elderly patients with low body mass index and inflammation compared with non-users.

Scientific reports·2026
Same author

Lower mortality in calcimimetic users compared to non-users in dialysis patients with serum parathyroid hormone levels within the target range.

Scientific reports·2025
Same author

Improved survival with high albumin leakage in patients with protein-energy wasting and inflammation on hemodialysis and online hemodiafiltration.

Scientific reports·2025
Same author

The association between renal medullary and cortical fibrosis, stiffness, and concentrating capacity: an observational, single-center cross-sectional study.

Clinical and experimental nephrology·2024
Same author

Clinical Efficacy and Safety of Low-Dose Pemafibrate in Patients With Severe Renal Impairment: A Retrospective Study.

Cureus·2024
Same author

Impact of Albumin Leakage on the Mortality of Patients Receiving Hemodialysis or Online Hemodiafiltration.

Journal of clinical medicine·2024
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Feb 26, 2026

Lentiviral-mediated Knockdown During Ex Vivo Erythropoiesis of Human Hematopoietic Stem Cells
14:22

Lentiviral-mediated Knockdown During Ex Vivo Erythropoiesis of Human Hematopoietic Stem Cells

Published on: July 16, 2011

13.7K

Levocarnitine Injections Decrease the Need for Erythropoiesis-Stimulating Agents in Hemodialysis Patients with Renal

Takashi Maruyama1, Terumi Higuchi2, Toshio Yamazaki2

  • 1Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan.

Cardiorenal Medicine
|July 25, 2017
PubMed
Summary

Levocarnitine injections effectively reduced erythropoiesis-stimulating agent (ESA) doses in hemodialysis patients with renal anemia. This treatment improved the erythropoietin responsiveness index (ERI), enhancing overall ESA therapy response.

Keywords:
Erythropoiesis-stimulating agentsErythropoietin responsiveness indexHemodialysisLevocarnitineRenal anemia

More Related Videos

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

20.5K
Analysis of Hematopoietic Stem Progenitor Cell Metabolism
12:20

Analysis of Hematopoietic Stem Progenitor Cell Metabolism

Published on: November 9, 2019

7.4K

Related Experiment Videos

Last Updated: Feb 26, 2026

Lentiviral-mediated Knockdown During Ex Vivo Erythropoiesis of Human Hematopoietic Stem Cells
14:22

Lentiviral-mediated Knockdown During Ex Vivo Erythropoiesis of Human Hematopoietic Stem Cells

Published on: July 16, 2011

13.7K
Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

20.5K
Analysis of Hematopoietic Stem Progenitor Cell Metabolism
12:20

Analysis of Hematopoietic Stem Progenitor Cell Metabolism

Published on: November 9, 2019

7.4K

Area of Science:

  • Nephrology
  • Hematology
  • Pharmacology

Background:

  • Renal anemia is a common complication in patients undergoing maintenance hemodialysis.
  • Erythropoiesis-stimulating agents (ESAs) are standard treatment, but efficacy can vary.
  • Levocarnitine is being investigated for its potential role in managing anemia.

Purpose of the Study:

  • To evaluate the efficacy of levocarnitine injections in patients with renal anemia on hemodialysis.
  • To determine if levocarnitine affects the required dose of ESAs.
  • To assess the impact of levocarnitine on the erythropoietin responsiveness index (ERI).

Main Methods:

  • A randomized controlled clinical trial involving 60 hemodialysis patients.
  • Patients were assigned to receive levocarnitine injections or no injection for 12 months.
  • Erythropoietin responsiveness index (ERI) was calculated to assess ESA therapy response.

Main Results:

  • Hemoglobin and hematocrit levels were maintained in both groups.
  • Levocarnitine group required significantly lower ESA doses at 6 and 12 months compared to baseline and the control group.
  • The ERI significantly decreased in the levocarnitine group, indicating improved ESA response.

Conclusions:

  • Levocarnitine administration can reduce ESA requirements in hemodialysis patients with renal anemia.
  • Levocarnitine improves the response to erythropoiesis-stimulating agent therapy.
  • Levocarnitine is a potential adjunctive therapy for managing renal anemia in hemodialysis patients.